Sinemet

Carbidopa An inhibitor of DOPA DECARBOXYLASE, preventing conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no antiparkinson actions by itself.

[1. A dopa decarboxylase inhibitor that does not enter the brain used in conjunction with levodopa in the treatment of Parkinson disease to reduce L-dopa dosage and mitigate side effects.

Molecular Formula: C₁₀H₁₆N₂O₅

InChI: InChI=1/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2/t10-;/m0./s1/f/h15H;

InChIKey: InChIKey=QTAOMKOIBXZKND-NQNDPJCNDK
SMILES: CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O

Names:
    Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)-
    Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
    Carbidopa hydrate
    carbidopa
    Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
    Lodosyn
    Sinemet
    S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
    (-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
    (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-propanoic acid hydrate
    38821-49-7

Registries:
    PubChem CID 38101
    PubChem ID 179362